/TEM
TEM Stock - Tempus AI, Inc.
Healthcare|Medical - Healthcare Information ServicesNASDAQ
$64.46+3.62%
+$2.25 (+3.62%) • Dec 19
53
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.32
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+53.8%upside
Target: $99.14
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TEM
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$63.82 – $65.10
TARGET (TP)$99.17
STOP LOSS$59.30
RISK/REWARD1:6.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta5.01
52W High$104.32
52W Low$31.36
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $693.40M | $531.82M | $320.67M | $257.85M | $188.00M |
| Gross Profit | $381.11M | $286.18M | $130.19M | $83.64M | $28.71M |
| Gross Margin | 55.0% | 53.8% | 40.6% | 32.4% | 15.3% |
| Operating Income | $-691,082,000 | $-196,083,000 | $-265,442,000 | $-243,711,000 | $-193,454,000 |
| Net Income | $-705,809,000 | $-214,118,000 | $-289,811,000 | $-259,192,000 | $-209,854,000 |
| Net Margin | -101.8% | -40.3% | -90.4% | -100.5% | -111.6% |
| EPS | $-4.60 | $-1.73 | $-1.97 | $-1.75 | $-1.49 |
Company Overview
Tempus AI, Inc. operates as a healthcare technology company. It engages in providing next generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers, pharmaceutical companies, biotechnology companies, researchers, and other third parties. The company offers Insights, a license library of linked clinical, molecular, and imaging de-identified data, as well as a suite of analytical services to analytic and cloud-and-compute tools to pharmaceutical and biotechnology companies; and Trials that provides clinical trial matching services to pharmaceutical companies. In addition, it operates Next; Algos, a suite of algorithmic tests in oncology; Hub, a desktop and mobile platform for ordering, managing, and receiving tests and patient results; and Lens, a platform for researchers and scientists to find, access, and analyze Tempus data. The company has a strategic collaborations agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
13
72%
Hold / Neutral
5
28%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
13 Bullish5 Neutral/Bearish
Price Targets
$61
Average Target
↓ 4.9% Downside
Now
$40
Low
$61
Average
$110
High
Based on 20 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 2nd 2025 | Morgan Stanley | Resumed | Overweight | $85 |
| October 21st 2025 | TD Cowen | Downgrade | Hold | $88 |
| October 20th 2025 | Canaccord Genuity | Initiation | Buy | $110 |
| September 2nd 2025 | H.C. Wainwright | Initiation | Buy | $90 |
| April 21st 2025 | BTIG Research | Initiation | Buy | $60 |
| February 25th 2025 | JP Morgan | Downgrade | Neutral | $55← $50 |
| February 12th 2025 | William Blair | Downgrade | Market Perform | - |
| February 5th 2025 | TD Cowen | Resumed | Buy | $74← $58 |
| December 13th 2024 | Wolfe Research | Initiation | Outperform | $60 |
| December 9th 2024 | Guggenheim | Initiation | Buy | $74 |
| November 11th 2024 | Stifel | Downgrade | Hold | $65← $45 |
| October 2nd 2024 | BofA Securities | Downgrade | Neutral | $60← $45 |
| August 12th 2024 | Piper Sandler | Initiation | Neutral | $40 |
| July 9th 2024 | BofA Securities | Initiation | Buy | $41 |
| July 9th 2024 | Loop Capital | Initiation | Buy | $48 |
Earnings History & Surprises
TEMBeat Rate
67%
Last 6 quarters
Avg Surprise
+4.6%
EPS vs Estimate
Beats / Misses
4/2
Last 12 quarters
Latest EPS
$-0.11
Q4 2025
EPS Surprise History
Q4 23
No data
Q2 24
No data
Q3 24
-6.8%
$-0.63vs$-0.59
Q4 24
+6.0%
$-0.25vs$-0.27
Q1 25
-20.0%
$-0.18vs$-0.15
Q2 25
+7.7%
$-0.24vs$-0.26
Q3 25
+4.3%
$-0.22vs$-0.23
Q4 25
+36.2%
$-0.11vs$-0.17
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 4, 2026 | — | — | — | — |
Q1 2026 | Feb 23, 2026 | $-0.05 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.17 | $-0.11 | +36.2% | ✓ BEAT |
Q3 2025 | Aug 8, 2025 | $-0.23 | $-0.22 | +4.3% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.26 | $-0.24 | +7.7% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $-0.15 | $-0.18 | -20.0% | ✗ MISS |
Q4 2024 | Nov 4, 2024 | $-0.27 | $-0.25 | +6.0% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $-0.59 | $-0.63 | -6.8% | ✗ MISS |
Q2 2024 | Jun 17, 2024 | — | $-0.38 | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.30 | — | — |
Q3 2023 | Sep 30, 2023 | — | $-0.31 | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.33 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.32 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.39 | — | — |
Q4 2021 | Dec 30, 2021 | — | $-0.35 | — | — |
Q3 2021 | Sep 29, 2021 | — | $-0.40 | — | — |
Q4 2020 | Dec 30, 2020 | — | $-0.32 | — | — |
Q3 2020 | Sep 29, 2020 | — | $-0.34 | — | — |
Q4 2016 | Nov 21, 2016 | $-0.32 | — | — | — |
Latest News
JP Morgan Maintains Neutral on Tempus AI, Lowers Price Target to $80
➖ NeutralBenzinga•Dec 15, 2025, 07:23 PM
Morgan Stanley Maintains Overweight on Tempus AI, Raises Price Target to $85
📈 PositiveBenzinga•Dec 2, 2025, 06:00 PM
BTIG Maintains Buy on Tempus AI, Raises Price Target to $105
📈 PositiveBenzinga•Nov 25, 2025, 12:20 PM
Tempus AI And Institute For Follicular Lymphoma Innovation Commence Study On Follicular Lymphoma
➖ NeutralBenzinga•Nov 14, 2025, 01:36 PM
Piper Sandler Maintains Neutral on Tempus AI, Lowers Price Target to $80
➖ NeutralBenzinga•Nov 11, 2025, 05:11 PM
Morgan Stanley Maintains Overweight on Tempus AI, Raises Price Target to $80
📈 PositiveBenzinga•Nov 11, 2025, 04:57 PM
HC Wainwright & Co. Maintains Buy on Tempus AI, Lowers Price Target to $89
📈 PositiveBenzinga•Nov 7, 2025, 12:07 PM
Canaccord Genuity Maintains Buy on Tempus AI, Lowers Price Target to $95
➖ NeutralBenzinga•Nov 5, 2025, 06:33 PM•Also:
Needham Maintains Buy on Tempus AI, Raises Price Target to $100
📈 PositiveBenzinga•Nov 5, 2025, 11:44 AM
Tempus AI shares are trading lower despite raising FY25 outlook.
📉 NegativeBenzinga•Nov 5, 2025, 11:42 AM
BTIG Reiterates Buy on Tempus AI, Maintains $96 Price Target
📈 PositiveBenzinga•Nov 5, 2025, 10:49 AM
Tempus AI falls despite Q3 double line beats, raising 2025 revenue guidance
➖ NeutralSeeking Alpha•Nov 4, 2025, 11:28 PM
Tempus AI shares are trading lower. The company reported Q3 financial results.
📉 NegativeBenzinga•Nov 4, 2025, 09:31 PM
Tempus AI Raises FY2025 Sales Guidance from $1.260B to $1.265B vs $1.260B Est
📈 PositiveBenzinga•Nov 4, 2025, 09:04 PM
Tempus AI Q3 Adj. EPS $(0.11) Beats $(0.17) Estimate, Sales $334.206M Beat $328.728M Estimate
📈 PositiveBenzinga•Nov 4, 2025, 09:02 PM
Piper Sandler Maintains Neutral on Tempus AI, Raises Price Target to $105
➖ NeutralBenzinga•Oct 22, 2025, 03:10 PM
BTIG Maintains Buy on Tempus AI, Raises Price Target to $96
📈 PositiveBenzinga•Oct 22, 2025, 12:17 PM
Tempus AI shares are trading higher after the company announces its subsidiary, Ambry Genetics, published a peer-reviewed study in Genetics in Medicine.
📈 PositiveBenzinga•Oct 20, 2025, 03:04 PM
Tempus AI's Ambry Genetics Announces The Publication Of A Peer-Reviewed Study In Genetics In Medicine; 10-Year Study Reveals Lower Provider-Initiated Exome Reanalysis Rates Among Diverse Groups, Highlights Need For Proactive Programs Like Ambry's Patient For Life Program
📈 PositiveBenzinga•Oct 20, 2025, 01:05 PM
Whitehawk Therapeutics shares are trading higher after the company announced a multi-year collaboration with Tempus AI to leverage Tempus' proprietary real-world dataset to advance biomarker-driven research and support the development of Whitehawk Therapeutics' oncology pipeline.
📈 PositiveBenzinga•Oct 16, 2025, 12:52 PM•Also:
Frequently Asked Questions about TEM
What is TEM's current stock price?
Tempus AI, Inc. (TEM) is currently trading at $64.46 per share. The stock has moved +3.62% today.
What is the analyst price target for TEM?
The average analyst price target for TEM is $99.17, based on 1 analyst.
What sector is Tempus AI, Inc. in?
Tempus AI, Inc. operates in the Healthcare sector, specifically within the Medical - Healthcare Information Services industry. The company is traded on the NASDAQ exchange.
What is TEM's market cap?
Tempus AI, Inc. has a market capitalization of $11.05 billion, making it a large-cap company.
Does TEM pay dividends?
No, Tempus AI, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCNC
Centene Corporation
$39.03
Mkt Cap: $19.2B
COO
The Cooper Companies, Inc.
$82.75
Mkt Cap: $16.5B
DOCS
Doximity, Inc.
$43.65
Mkt Cap: $8.2B
FMS
Fresenius Medical Care AG & Co. KGaA
$23.51
Mkt Cap: $13.8B
HOLX
Hologic, Inc.
$74.95
Mkt Cap: $16.7B
ICLR
ICON Public Limited Company
$173.77
Mkt Cap: $13.3B
MEDP
Medpace Holdings, Inc.
$568.36
Mkt Cap: $16.0B
NBIX
Neurocrine Biosciences, Inc.
$145.00
Mkt Cap: $14.4B
SNN
Smith & Nephew plc
$32.82
Mkt Cap: $14.4B
UHS
Universal Health Services, Inc.
$227.46
Mkt Cap: $14.7B
Explore stocks similar to TEM for comparison